Founded
31 Dec 2008
Website
VCID: 409911
Profile
Corporate information
Registration country
Registration country
Investment activity status
Not investing
Company type
Cancer drug development company.Funding
Funding rounds
Acquisition USD 10,200,000,000
USD 10,200,000,000 (28 Apr 2016) at USD 10,200,000,000 valuation.
The deal includes USD5.8 billion in upfront payments, includingUSD2 billion in stock, as well as USD4 billion in cash-based earnouts, plus a return to shareholders of Stemcentrx of cash on hand.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Abbvie Inc | United States | 10,200,000,000 (USD 10,200,000,000). Initial investment. Round participant. |
Series G USD 250,000,000
USD 250,000,000 (1 Sep 2014)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Artis Ventures | Venture capital firm | United States |
Series F USD 200,000,000
USD 200,000,000 (1 May 2014)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
Artis Ventures | Venture capital firm | United States |
Series C USD 23,530,000
USD 23,530,000 (1 Mar 2011)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
Artis Ventures | Venture capital firm | United States |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
OakHouse Partners | United States | via Alpha Fund, Initial investment. Round participant. |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Abbvie Inc |
+1 (847) 932-7900 |
Acquisition |
|
|
Artis Ventures Venture capital firm |
Series C Series F Series G |
|
|
|
OakHouse Partners |
N/A (exited) |